Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia
Abstract T-cell acute lymphoblastic leukemia (T-ALL) is one of the hematological malignancies. With the applications of chemotherapy regimens and allogeneic hematopoietic stem cell transplantation, the cure rate of T-ALL has been significantly improved. However, patients with relapsed and refractory...
Main Authors: | Ruyue Zheng, Menglin Li, Shujuan Wang, Yanfang Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-11-01
|
Series: | Experimental Hematology & Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40164-020-00187-x |
Similar Items
-
Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults
by: Khalil Saleh, et al.
Published: (2022-04-01) -
Gamma-secretase inhibitor does not induce cytotoxicity in adult T-cell leukemia cell lines despite NOTCH1 expression
by: Shinsuke Suzuki, et al.
Published: (2022-10-01) -
Targeting oncogenic Notch signaling with SERCA inhibitors
by: Luca Pagliaro, et al.
Published: (2021-01-01) -
Notch Partners in the Long Journey of T-ALL Pathogenesis
by: María Luisa Toribio, et al.
Published: (2023-01-01) -
Isatuximab monotherapy in patients with refractory T‐acute lymphoblastic leukemia or T‐lymphoblastic lymphoma: Phase 2 study
by: Nicolas Boissel, et al.
Published: (2022-03-01)